The market’s animal spirits for any company that
even whispers “coronavirus vaccine” is in full display with thinly
traded nano cap Capricor Therapeutics (CAPR +55.2%).
Shares are up on a healthy 28x surge in volume in response to its announced Key Opinion Leader call
on why exosomes are “uniquely suited” for vaccine development. Company
consultant Stephen J. Gould, Ph.D., a Professor of Biological Chemistry
at Johns Hopkins University, will provide an overview of an approach to
exosome-based research, including its applicability to a potential
COVID-19 vaccine, on Thursday, March 26, at 12:00 pm ET.
Exosomes are
one of the company’s two (the other is cell therapy) platforms. The
company says they act as messengers to regulate functions of neighboring
or distant cells, playing key roles in cell survival and proliferation,
inflammation and tissue regeneration.
https://seekingalpha.com/news/3554727-capricor-up-55-on-potential-of-exosome-platform-for-coronavirus-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.